Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RH5.1 + AS01B
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
RH5.1 + AS01B (also written as RH5.1/AS01B) is an investigational asexual blood-stage malaria vaccine candidate developed by the University of Oxford. The vaccine consists of RH5.1, a recombinant soluble full-length Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) antigen, formulated with GlaxoSmithKline's (GSK) liposome-based adjuvant system AS01B. The RH5.1 antigen is produced in Drosophila melanogaster S2 cells using ExpreS2ion Biotechnologies' ExpreS2 platform. PfRH5 is a highly conserved merozoite surface protein essential for the invasion of human erythrocytes via its interaction with the host receptor basigin (CD147). By eliciting neutralizing antibodies that block this interaction, the vaccine aims to prevent blood-stage P. falciparum infection and reduce parasite multiplication rates. In the Phase I/IIa VAC063 clinical trial (NCT02927145) in healthy, malaria-naïve UK adults, RH5.1 + AS01B demonstrated a favorable safety profile, robust immunogenicity, and a significant reduction in parasite growth rate following controlled human malaria infection (CHMI).
- Other names
- RH5.1 + AS01^BRH5.1/AS01^B
02
Targets
PfRH5
Beyond the preview
Go deeper on RH5.1 + AS01B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RH5.1 + AS01B.